Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 71 Neoplasm Metastasis 26 Stomach Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 10 Neoplasms 8 Brain Neoplasms 8 Adenocarcinoma 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Esophageal Neoplasms 4 Endometrial Neoplasms 4 Salivary Gland Neoplasms 3 Recurrence 3 HER2-positive Breast Cancer 3 Advanced Solid Tumor 3 Advanced Breast Cancer 3 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm, Residual 2 Meningeal Carcinomatosis 2 Melanoma 2 HER2-positive Gastric Cancer 2 Gastrointestinal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Renal Cell 2 Breast Cancer With Brain Metastasis 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1

Interventions

eribulin 3 Vinorelbine 2 Paclitaxel 2 Epirubicin 2 Doxorubicin 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 anlotinib 1 Taxes 1 Precision Medicine 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × trastuzumab deruxtecan × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡